Home >> Signaling Pathways >> Apoptosis

Apoptosis(凋亡)

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

Products for  Apoptosis

  1. Cat.No. 产品名称 Information
  2. GC14247 GDC-0623

    RG 7421; MEK inhibitor 1

    A potent, ATP-uncompetitive inhibitor of MEK1
  3. GC14756 EI1

    6-氰基-N-[(1,2-二氢-4,6-二甲基-2-氧代-3-吡啶基)甲基]-1-(1-乙基丙基)-1H-吲哚-4-甲酰胺,KB-145943

    A selective inhibitor of EZH2
  4. GC17331 Salubrinal Salubrinal是有效的选择性真核翻译起始因子2α(eIF2α)去磷酸化抑制剂。
  5. GC14498 AP20187

    B/B Homodimerizer

    A CID for FKBP fusion proteins
  6. GC17430 2-Deoxy-D-glucose

    2-脱氧-D-葡萄糖; 2-DG; 2-Deoxy-D-arabino-hexose; D-Arabino-2-deoxyhexose

    2-Deoxy-D-glucose (2DG),是一种葡萄糖类似物,作为竞争性糖酵解抑制剂。
  7. GC14063 GSK1324726A

    I-BET726

    A selective inhibitor of BET family proteins
  8. GC11648 BML-277

    Chk2 Inhibitor II

    A selective DNA damage control kinase inhibitor
  9. GC13359 Topotecan HCl

    盐酸拓扑替康; SKF 104864A Hydrochloride; NSC 609669 Hydrochloride

    A potent inhibitor of DNA topoisomerase I
  10. GC11669 Tamoxifen Citrate

    他莫昔芬柠檬酸盐; ICI 46474; (Z)-Tamoxifen Citrate; trans-Tamoxifen Citrate

    A selective estrogen receptor modulator
  11. GC16233 Tacrolimus (FK506)

    他克莫司; FK506; Fujimycin; FR900506

    他克莫司 (FK506) 是一种具有强效免疫抑制作用的大环内酯类抗生素,从筑波链霉菌中分离出来,以前曾用于预防人类同种异体移植和治疗自身免疫性疾病。
  12. GC17865 Lomustine

    洛莫司汀; CCNU; NSC 79037

    A DNA alkylating agent
  13. GC17778 TAME

    N-[(4-甲基苯基)磺酰基]-L-精氨酸甲酯

    TAME 是后期促进复合物/环体(APC/C 或 APC)的抑制剂,它与 APC/C 结合并阻止其被 Cdc20 和 Cdh1 激活,产生有丝分裂停滞。 TAME 不具有细胞渗透性。
  14. GC11177 GDC-0980 (RG7422)

    (S)-1-[4-[[2-(2-氨基嘧啶-5-基)-7-甲基-4-(吗啉-4-基)噻吩并[3,2-D]嘧啶-6-基]甲基]哌嗪-1-基]-2-羟基丙-1-酮,GDC-0980; GNE 390; RG 7422

    A dual inhibitor of PI3K and mTOR
  15. GC11078 MRS 2578 A selective antagonist of the purinergic P2Y6 receptor
  16. GC10354 Daunorubicin HCl

    盐酸柔红霉素; Daunomycin hydrochloride; RP 13057 hydrochloride; Rubidomycin hydrochloride

    Antitumor antibiotic used in the treatment of acute myeloid leukemias
  17. GC14007 DCC-2036 (Rebastinib)

    N-[3-叔丁基-1-(喹啉-6-基)-1H-吡唑-5-基]-N'-[2-氟-4-[(2-(甲基氨基甲酰基)吡啶-4-基)氧]苯基]脲,DCC-2036

    An orally bioavailable tyrosine kinase inhibitor
  18. GC13858 Torin 2

    9-(6-氨基-3-吡啶基)-1-[3-(三氟甲基)苯基]苯并[H]-1,6-萘啶-2(1H)-酮

    Selective inhibitor of mTOR
  19. GC12531 Cabozantinib malate (XL184)

    卡博替尼苹果酸盐; XL184 S-malate; BMS-907351 S-malate

    A VEGFR2 inhibitor
  20. GC12415 Rigosertib

    瑞格色替; ON-01910

    Rigosertib (ON-01910) 是一种多激酶抑制剂和选择性抗癌剂,通过抑制 PI3 激酶/Akt 通路诱导细胞凋亡,促进组蛋白 H2AX 的磷酸化并诱导细胞周期 G2/M 停滞。 Rigosertib 是一种选择性和非 ATP 竞争性的 PLK1 抑制剂,IC50 为 9 nM。
  21. GC13580 Rigosertib sodium

    瑞格色替钠,ON-01910 sodium

    Rigosertib sodium (ON-01910 sodium) 是一种多激酶抑制剂和选择性抗癌剂,通过抑制 PI3K/Akt 通路诱导细胞凋亡,促进组蛋白 H2AX 的磷酸化并诱导细胞周期 G2/M 停滞。 Rigosertib sodium 是一种选择性和非 ATP 竞争性的 PLK1 抑制剂,IC50 为 9 nM。
  22. GC11018 GSK1059615

    (5Z)-5-[[4-(4-吡啶基)-6-喹啉基]亚甲基]-2,4-噻唑烷二酮

    A potent PI3K inhibitor
  23. GC11537 MK-4827 tosylate

    尼拉帕尼对苯甲磺酸盐; MK-4827 tosylate

    An orally bioavailable PARP1/2 inhibitor
  24. GC12756 MK-4827 hydrochloride

    MK-4827 hydrochloride

    MK-4827 hydrochloride (MK-4827 hydrochloride) 是一种高效且具有口服生物利用度的 PARP1 和 PARP2 抑制剂,IC50 分别为 3.8 和 2.1 nM。 MK-4827 hydrochloride 抑制 DNA 损伤的修复,激活细胞凋亡并显示出抗肿瘤活性。
  25. GC11685 GW5074 A potent inhibitor of Raf-1
  26. GC11003 PP121 A potent dual inhibitor of tyrosine and phosphoinositide kinases
  27. GC17651 Sunitinib

    舒尼替尼; SU 11248

    舒尼替尼Sunitinib(SU 11248)是一种具口服活性的多靶点受体酪氨酸激酶抑制剂,对血管内皮生长因子受体(VEGFR2)和血小板衍生生长因子受体(PDGFRβ)的IC50分别为80nM和2nM。
  28. GC15254 Tandutinib (MLN518)

    坦度替尼; MLN518; CT53518

    An antagonist of PDGFRβ, FLT3, and c-Kit
  29. GC14675 WYE-125132 (WYE-132)

    N-[4-[1-(1,4-二氧杂螺[4.5]癸烷-8-基)-4-(8-氧杂-3-氮杂双环[3.2.1]辛烷-3-基)-1H-吡唑并[3,4-D]嘧啶-6-基]苯基]-N'-甲基脲,WYE-125132

    Dual mTORC1/mTORC2 inhibitor
  30. GC13232 Verbascoside

    麦角甾苷; Acteoside; Kusaginin; TJC160

    A natural phenylpropanoid glucoside with diverse biological activities
  31. GC16296 MI-773

    (2'R,3S,4'S,5'R)-6-氯-4'-(3-氯-2-氟苯基)-2'-(2,2-二甲基丙基)-1,2-二氢-N-(反式-4-羟基环己基)-2-氧代螺[3H-吲哚-3,3'-吡咯烷]-5'-甲酰胺

    MI-773 是一种有效的 MDM2-p53 蛋白-蛋白相互作用 (PPI) 抑制剂,对 MDM2 具有高结合亲和力 (Kd=8.2 nM)。 MI-773 具有抗肿瘤活性。
  32. GC11439 MG 149

    Tip60 HAT inhibitor

    A HAT inhibitor
  33. GC11488 TCS JNK 5a

    JNK Inhibitor IX

    A selective inhibitor of JNK2 and JNK3
  34. GC12891 CCT007093

    (2E,5E)-2,5-二(2-噻吩基亚甲基)环戊酮

    An inhibitor of PPM1D
  35. GC14755 Inauhzin

    INZ

    A selective SIRT1 inhibitor
  36. GC14312 Meisoindigo

    甲异靛; Dian III; N-Methylisoindigotin; Natura-α

    An anticancer agent
  37. GC10734 Beta-Lapachone

    3,4-二氢-2,2-二甲基-2H-萘并[1,2-B]吡喃-5,6-二酮,ARQ-501; NSC-26326

    An anti-cancer quinone
  38. GC16701 SKI II

    鞘氨醇激酶抑制剂

    An SPHK1 inhibitor
  39. GC11068 GSK2656157 A PERK inhibitor
  40. GC10692 Caffeic Acid Phenethyl Ester

    咖啡酸苯乙酯

    A potent inhibitor of NF-κB activation
  41. GC14364 SGI-1027

    DNA Methyltransferase Inhibitor II

    A DNA methyltransferase inhibitor
  42. GC15603 JIB-04

    5-氯-2(1H)-吡啶酮(2E)-(苯基-2-吡啶基亚甲基)腙

    A pan Jumonji histone demethylase inhibitor
  43. GC15771 PYR-41 An irreversible inhibitor of ubiquitin-activating enzyme
  44. GC12011 P276-00

    P276-00

    P276-00 (P276-00) 是一种有效的细胞周期蛋白依赖性激酶 (CDK) 抑制剂,可抑制 CDK9-cyclinT1、CDK4-cyclin D1 和 CDK1-cyclinB,IC50 分别为 20 nM、63 nM 和 79 nM。 P276-00 (P276-00) 对顺铂耐药细胞具有抗肿瘤活性。
  45. GC10294 Tasisulam

    他斯索兰,LY 573636

    An anticancer agent
  46. GC16990 Z-LEHD-FMK Z-LEHD-FMK 是一种选择性且不可逆的 caspase-9 抑制剂,可防止致命的再灌注损伤并减轻细胞凋亡。
  47. GC12407 Z-IETD-FMK

    CASPASE-8抑制剂,Benzyloxycarbonyl-Ile-Glu(OMe)-Thr-Asp(OMe)-fluoromethylketone, Z-Ile-Glu(OMe)-Thr-Asp(OMe)-FMK

    Z-IETD-FMK(Z-IE(OMe)TD(OMe)-FMK)是一种选择性和细胞可渗透的 caspase-8抑制剂。
  48. GC10345 Bay 11-7085

    (2E)-3-[[4-叔丁基苯基]磺酰基]-2-丙烯腈,BAY 11-7083

    An irreversible inhibitor of IκBα phosphorylation
  49. GC13592 PD173955

    6-(2,6-二氯苯基)-8-甲基-2-[[3-(甲硫基)苯基]氨基]吡啶并[2,3-D]嘧啶-7(8H)-酮

    A tyrosine kinase inhibitor
  50. GC10442 MK-8745 An Aurora A kinase inhibitor
  51. GC15828 AMG232

    2-((3R,5R,6S)-5-(3-氯苯基)-6-(4-氯苯基)-1-((S)-1-(异丙基磺酰基)-3-甲基丁烷-2-基)-3-甲基-2-氧代哌啶-3-基)乙酸,AMG 232;AMG-232

    An inhibitor of the MDM2 and p53 interaction

Items 2201 to 2250 of 2733 total

per page

Set Descending Direction